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Summary The EVI-I gene was originally detected as an ectopic viral insertion site and encodes a nuclear zinc
finger DNA-binding protein. Previous studies showed restricted EVI-1 RNA or protein expression during
ontogeny; in a kidney and an edometrial carcinoma cell line; and in normal murine oocytes and kidney cells.
EVI-1 expression was also detected in a subset of acute myeloid leukaemias (AMLs) and myelodysplasia.
Because EVI-1 is expressed in the urogenital tract during development, we examined ovarian cancers and
normal ovaries for EVI-1 RNA expression using reverse transcription-polymerase chain reaction (RT-PCR)
and RNAase protection. Chromosome abnormalities were examined using karyotypes and whole chromosome
3 and 3q26 fluorescence in situ hybridisation (FISH). RNA from six primary ovarian tumours, five normal
ovaries and 47 tumour cell lines (25 ovarian, seven melanoma, three prostate, seven breast and one each of
bladder, endometrial, lung, epidermoid and histiocytic lymphoma) was studied. Five of six primary ovarian
tumours, three of five normal ovaries and 22 of 25 ovarian cell lines expressed EVI-1 RNA. A variety of other
non-haematological cancers also expressed EVI-1 RNA. Immunostaining of ovarian cancer cell lines revealed
nuclear EVI-1 protein. In contrast, normal ovary stained primarily within oocytes and faintly in stroma.
Primary ovarian tumours showed nuclear and intense, diffuse cytoplasmic staining. Quantitation of EVI-1
RNA, performed using RNAase protection, showed ovarian carcinoma cells expressed 0 to 40 times the EVI-I
RNA in normal ovary, and 0-6 times the levels in leukaemia cell lines. Southern analyses of ovarian
carcinoma cell lines showed no amplification or rearrangements involving EVI-1. In some acute leukaemias,
activation of EVI-1 transcription is associated with translocations involving 3q26, the site of the EVI-I gene.
Ovarian carcinoma karyotypes showed one line with quadruplication 3(q24q27), but no other clonal structural
rearrangements involving 3q26. However, whole chromsome 3 and 3q26 FISH performed on lines with high
EVI-1 expression showed translocations involving chromosome 3q26. EVI-1 is overexpressed in ovarian cancer
compared with normal ovaries, suggesting a role for EVI-1 in solid tumour carcinogenesis or progression.
Mechanisms underlying EVI- 1 overexpression remain unclear, but may include rearrangements involving
chromosome 3q26.
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Ovarian cancer is the leading cause of death from female
genitourinary cancers in the United States (Boring et al.,
1994). Compared with other solid tumours, relatively little is
known regarding the molecular pathogenesis and progression
of ovarian cancers. Mutations and/or altered expression of
p53 (Marks et al., 1991; Milner et al., 1993) and HER-2/neu
(Rubin et al., 1993, 1994) occur frequently, but ras mutations
are relatively infrequent (van't Veer et al., 1988; Smith et al.,
1989) compared with other solid tumours. Sporadic reports
of abnormal expression of other proto-oncogenes, including
myc,fos, AKT2 and int-2 have appeared (Sasano et al., 1990;
Cheng et al., 1992), but the roles of these genes in ovarian
carcinogenesis and the relative frequencies of their expression
in ovarian cancers remain unclear.
The EVI-I (ecotropic virus integration-1) gene was
originally detected as a murine virus insertion site in
experimental leukaemias (Mucenski et al., 1988) and
localised to human chromosome band 3q26 (Morishita et
al., 1990a). The gene encodes a nuclear zinc finger protein
with specific DNA-binding properties (Matsugi et al., 1990;
Perkins et al., 1991a; Delwel et al., 1993). The function of
EVI-I in normal cells remains unknown, but it is sequentially
expressed in limb buds during ontogeny, suggesting a role in
cell migration (Perkins et al., 1991b). During embryological
development in mice, EVI-1 protein is expressed at high levels
in restricted sites including the urinary and Mullerian
systems, bronchial epithelium, focal areas in nasal cavities,
endocardial cushions, and developing limbs (Perkins et al.,
1991b). Recent data suggest EVI-l alters transcription
directed by other Zn finger genes, such as GATA-l (Kreider
et al., 1993) and regulates c-fos expression (Tanaka et al.,
1994), thus controlling gene expression.
In normal adult murine tissues, EVI- 1 expression was
previously detected in murine kidney tubules and oocytes
(Perkins et al., 199 ib; Morishita et al., 1990c). The presence of
EVI-l protein has also been demonstrated in human kidney
and endometrial tissues (Kreider et al., 1993) and EVI-l RNA
was induced in short-term culture of kidney tubule cells by
cAMP (Bartholomew and Clark, 1994). Using Northern
analysis, expression of EVI- 1 RNA was detected in only a
few human solid tumour cell lines (Morishita et al., 1990b).
Because EVI-1 is expressed in developing urogenital tract
and normal oocytes, we examined its expression in normal
human ovary and ovarian cancers. Using reverse transcrip-
tion -polymerase chain reaction (RT -PCR), EVI-1 RNA
was detected in the vast majority of ovarian cancers and in
many other solid tumours. Some ovarian tumours expressed
extremely high levels of EVI-l RNA compared with normal
ovary, suggesting that the EVI-I gene may play a role in
pathogenesis or progression of ovarian cancers.
Methods
Tumour specimens
Primary ovarian cancer tissue specimens were obtained from
untreated patients (Thompson et al., 1994). All specimens,
including those used to establish cell lines from tumours,
were obtained as excess pathological material using
procedures approved by the Committee on Human Sub-
jects, University of Arizona. Primary tumours and normal
ovaries were stored frozen at -70°C until used. Four of five
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normal ovaries studied contained both oocytes and stromal
elements. The fifth, obtained from a post-menopausal patient,
contained no oocytes. Previously established cancer cell lines
were maintained using RPMI-1640 medium with either 5%
or 10% fetal bovine serum (FBS), except the HECIb
endometrial carcinoma (Morishita et al., 1990b) line, which
was maintained in minimum essential median (MEM) with
10% FBS. These lines included: OVCAR3 (Cheng et al.,
1992), SKOV3 (Buick et al., 1985), 2008 (Naredi et al., 1994),
2780 (Mann et al., 1991), 367 (Taetle and Honeysett, 1987)
and Colo-316 (Woods et al., 1979). Ovarian carcinoma cell
lines established from primary tumours were designated
UACC (numbers 469, 1598, 326, 188, 591, 1763, 2614,
1703, 2996, 2983, 2727, 295, 1499, 2980, 1123, 2982, 341,
2912 and 2661) and characterised and maintained as
previously described (Leibowitz, 1986). Melanoma cell lines
developed from primary tumours were also assigned UACC
numbers (475, 502 and 2946). In addition, three previously
described melanoma lines, 355, 242 (Taetle et al., 1987) and
289 (Taetle and Honeysett, 1987) were tested. With the
exception of MDA 468 (Taetle et al., 1988), all breast tumour
cell lines were developed at the University of Arizona, and
included UACC numbers 2642, 2715, 2436, 245, 812 and 893.
All UACC cell lines were established from primary tumour
tissue and the original diagnosis confirmed by independent
pathology review. Factor-dependent UCSD/AML1 and
factor-independent HEL leukaemia cells expressing EVI-1
RNA were maintained as described previously (Russell et al.,
1993, 1994; Oval et al., 1990). Other lines studied included
prostate [PC3 (Rodan et al., 1983), LN CaP (Wilding et al.,
1990), DU 146 (Mickey et al., 1980)], epidermoid [A431
(Taetle et al., 1988)], lung (A375), AML (HL60) and
histiocytic lymphoma cells, U937 (Russell et al., 1994).
Immunostaining
Carcinoma cell lines were harvested using custom ATV (0.5%
trypsin, 12% EDTA, sodium bicarbonate) (Irvine Scientific
Santa Ana, CA, USA) trypsin. Cytospin preparations were
made on aminopropyltriethoxysilane (Sigma, St Louis, MO,
USA)-treated slides for immunostaining. Tumour tissue was
frozen or fixed in 10% neutral-buffered formalin and
processed in paraffin as routine surgical pathology speci-
mens. Blocks were stored at room temperature.
Formalin-fixed tissue was sectioned on poly-L-lysine-
coated slides and baked at 60°C for 20 min immediately
before staining. The slides were deparaffinised In xylene for
2 min twice, then rehydrated in 100%, 85% and 70%
ethanol. Cytospin preparations were prepared as above, air-
dried at 4°C for 1-2 h and fixed in a solution of 1%
formalin and 1% Triton X in water for 20 min at room
temperature. Fixed slides were washed in two changes of
phosphate-buffered saline (PBS) for 3 min each. The slides
were then covered with a 1: 250 dilution of anti EVI-1 anti-
serum (Matsugi et al., 1990) (kindly provided by Dr James
Ihle, St Jude's Hospital, Memphis, TN, USA) or rabbit
serum (1: 250; Cappel, Durham, NC, USA) as a negative
control, in a dark humidified chamber.
After incubation, slides were rinsed in three changes of
1 x PBS for 3 min each. Biotinylated swine anti-rabbit
antibody (Dako, Carpinteria, CA, USA) diluted 1: 300 was
placed on the slides in a dark, humidified chamber at room
temperature for 30 min. The slides were then rinsed as
described above. EVI-I protein was detected using alkaline
phosphatase or horseradish peroxidase-conjugated streptavi-
din (Guesdon et al., 1995). Known EVI-1-positive (UCSD/
AML1, HEL or HEC1b) and -negative (ovarian 2780 or
HL60 leukaemia) cells were stained concurrently.
RNA polymerase chain reaction
EVI-1 RNA was detected using reverse transcription -
polymerase chain reaction (RT-PCR) as previously de-
scribed (Russell et al., 1994) with modifications. RNA was
prepared by lysis and extraction from cells with Trizol (Gibco
BRL, Gaithersberg, MD, USA), according to the manufac-
turer's instructions. Reverse transcription of approximately
0.1-0.5 ,ug RNA was performed for 45 min at 37°C in a
solution containing the following components in final
concentrations: 1 x Taq reaction buffer (Boehringer Man-
nheim) with an additional 5 mM magnesium chloride, 1 mM
dNTPs (Perkin Elmer); 2.5 pM pl-' Oligo dtl5 primer
(Boehringer Mannheim); 1 U il` RNAasin (RNAase
inhibitor from Promega); 2.5 U ul-' MMLV reverse tran-
scriptase (Gibco/BRL). The amplification mixture contained
(final concentrations): 10 mM Tris-HCl at pH 8.3; 1.5 mM
magnesium chloride; 50 mM potassium chloride; 3 ng ,ul-'
each of 5' and 3' primer (Biosynthesis, Lewisville, TX, USA);
and Taq DNA polymerase at 1.25 units per reaction
(Boehringer Mannheim, Indianapolis, IN, USA). The PCR
was run for one cycle at 92°C for 5 min, then 30 cycles at
92°C for 1 min, at 62°C for 1 min and at 72°C for 2 min,
plus an additional cycle with 15 min extension at 72°C. In
each study, UCSD/AML1 or HEL RNA (EVI-1-positive)
and HL60 leukaemia cell or 2780 ovarian cancer RNA (EVI-
1-negative) plus a mock reaction containing no RNA was
performed. Primers spanned bases 223-702 (5' EVI-1
product) and 2110-2390 (3' EVI-1 products) of the EVI-1
coding sequence (Morishita et al., 1990b). The 3' EVI-1
reverse PCR yields two characteristic products of 254 and
272 bases owing to alternative splicing (Russell et al., 1994).
Histone or GAPDH (available for later experiments) RNA
was assessed in parallel to assure RNA integrity (Russell et
al., 1994).
Identity of EVI-1 PCR products was verified by probing
Southern blots of RT-PCR products with an oligonucleotide
internal to the priming sequences (Russell et al., 1993). Both
3' EVI-I PCR products from two cell lines, Colo316 and
SKOV-3, were also sequenced using automated techniques
(Scripps Clinic and Research Foundation, La Jolla, CA,
USA), and yielded the expected EVI-1 sequences (Morishita
et al., 1990b).
Assessment of EVI-I RNA expression
EVI-1 RNA content was evaluated using RNAase protection.
For RNAase protection, a cDNA segment corresponding to
the 272 bp EVI-1 RT-PCR (Russell et al., 1994) product
was cloned into the PCII (Clontech, Palo Alto, CA, USA)
vector and transcribed using Maxiscript (Ambion, Austin,
TX, USA) in vitro transcription kit, according to the
manufacturer's instructions. The resulting probe had an
average specific activity of approximately 2 x 108 c.p.m. ug-'
and was gel purified. The probe was hybridised with 10 jIg
total RNA from cell lines or 40 Yg patient RNA using a
RPAII (Ambion) ribonuclease (RNAase) protection assay
kit. RNAase protection was performed using RNA from cell
lines, HEL (positive control) and HL60 (negative control);
ovarian carcinomas, SKOV-3, Colo-316, 367, 2780, 2008,
UACC 1598, UACC 326, UACC 2727 and UACC 295; and
prostate cancers, PC3 and DU-143. A previous study, using
UCSD/AML-1 RNA showed RT-PCR to be approximately
300 times more sensitive than RNAase protection (Russell et
al., 1994). Using phosphor-imaging of the RNAase products
(Molecular Dynamics, Sunnyvale, CA, USA), a linear
relationship between signal intensity and the amount of
RNA was present over at least a 1 log range of UCSD/
AMLI RNA. A GAPDH control probe (Ambion) was
labelled to approximately 50% of the activity of the EVI-1
probe, and hybridised in either a different or the same tube to
cell line RNA. These results were used to verify RNA
integrity and to normalise EVI-l results in calculating RNA
content.
RNA levels were also assessed by Northern analyses or
slot blots as previously described (Oval et al., 1992). Total
cell RNA was extracted as described above and Northern or
slot blots probed with a PCR-generated 272 bp probe,
corresponding to the RNAase protection assay. Blots wereEVI-1 in ovarian cancer
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normalised for RNA loading using a ,B-actin probe (Oval et
al., 1992; Taetle et al., 1991). RNA half-lives were estimated
by culturing cells with 10 jug ml-' actinomycin-D for 2 and
4 h as described (Oval et al., 1992). Responses to 10 ug/ml
cycloheximide were assessed in a similar fashion.
Southern blot analysis
DNA prepared from normal donor lymphocytes, UCSD/
AML1 cells (Oval et al., 1992), and carcinoma cell lines
OVCAR3, SKOV-3, 2780, 2008, Colo-316, UACC 1598 and
UACC 295 was digested with EcoRI, BamHI or both
enzymes and electrophoresed in 0.9% agarose gels. DNA
products were transfered to nylon filters as previously
described (Taetle et al., 1991) and hybridised with a PCR-
generated, digoxinin-labelled probe to EVI-1 5' flanking
sequences from -486 to -974 base pairs (Madden et al.,
1991); a 2.0 kb probe containing human 5' flanking and
coding sequences (Morishita et al., 1990b); and a full-length,
murine EVI-1 cDNA (Oval et al., 1992). Blots were stripped
and probed for actin to ensure DNA integrity. EVI-I DNA
content was expressed relative to normal ovary or
lymphocyte DNA probed on the same blot.
Karyotypes andfluoroscence in situ hybridisation (FISH)
Cell line karyotypes were performed as described (Thompson
et al., 1994). Whole chromosome 3 FISH was performed
according to manufacturer's instructions (Oncor, Gaithers-
burg, MD, USA) (Pinkel et al., 1988). A human 3q26, band-
specific probe was created by microdissection of normal
chromosome 3 and labelled as previously described (Guan et
al., 1995; Thompson et al., 1995). Hybridisation and FISH
were performed as described previously (Guan et al., 1995;
Thompson et al., 1995).
Results
Previous studies using Northern anlayses suggested EVI- 1
RNA expression was highly restricted among established
human, non-haematological, tumour cell lines (Morishita et
al., 1990b). In contrast, using RT-PCR, EVI-I RNA
products of 254 and 272 bp (because of alternate splicing)
were detected in five of six established ovarian cancer cell
lines. Cell line 2780 was consistently negative using RT-PCR
direct at both 5' (not shown) and 3' EVI-1 coding sequences
(Figure la), indicating truncated EVI-I transcripts were not
present. This result for 2780 cells was also verified using
immunostaining and RNAase protection (see below). EVI-I
RNA expression was previously induced in primary kidney
cells by cAMP (Bartholomew and Clark, 1994) and acute
promyelocytic leukaemia cells by all-trans retinoic acid
(Taetle et al., 1995). However, cAMP (10-7 or 10-6 M) all-
trans retinoic acid (10-6 or 10-7 M) failed to induce EVI-1
RNA expression detected by RT-PCR in 2780 ovarian
carcinoma cells. Similarly, 17 of 19 ovarian lines established
within the Arizona Cancer Center and tested at passages <20
also expressed EVI-I RNA (for example, Figure lb). All cell
lines positive for 3' EVI-1 PCR products were also positive
using 5' product primers. The latter encompass the major
start site and first 434 bp of the coding sequence. Thus all
cells positive for EVI-I RNA appeared to contain full-length
transcripts.
Frozen primary tumour specimens (six ovarian epithelial
and one ovarian sarcoma) were also positive for EVI-1 RNA
using RT-PCR (Table I). Four of four ovaries obtained
from premenopausal patients, which were histologically
normal except for the presence of follicular cysts, contained
low but detectable levels of EVI-1 RNA. RT-PCR of a
normal post-menopausal (oocyte-poor) ovary did not contain
EVI-I RNA. RT-PCR was also used to assess EVI-I
expression in non-ovarian tumour cells and normal fibro-
blasts and was detected in the majority of these cells (Table
a L 1 2 3 4 5 6 7 8
EVI
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Figure 1 (a) Detection of EVI-l RNA by RT-PCR in
established ovarian carcinoma cell lines: 3' EVI-l yields a
doublet of 254 and 272bp owing to alternate splicing. HL60
(lane 2) and HEL (lane 3) serve as negative and positive controls
respectively. Ovarian cell lines from left to right in lanes 4-8
include SKOV3, 367, 2780, Colo-316 and 2008. Cell line 367 (lane
5) yields a barely detectable, but consistently positive, signal, and
2780 is consistently negative. Bottom panels show GAPDH
controls. L, a 100 base pair ladder; lane 1, mock control. (b)
RNA PCR for EVI-l RNA in newly established cell cultures from
ovarian carcinomas. HL60 and HEL again serve as controls
(lanes 2 and 10 respectively). Lanes 3-8 are UACC cell line 1598,
326, 188, 2614, 1763 and 469. Bottom panel shows histone
controls. Lane 1, mock reaction (no RNA).
Table I EVI-l expression by RNA PCR
EVI-I RNA
Cell lines
Leukaemia/lymphoma (Russell et al., 1994) 3/12
Ovarian carcinoma 22/25
Melanoma 6/7
Endometrium (HECIB) 1/1
Breast 4/7
Prostrate 3/3
Bladder 1/1
Epidermoid carcinoma 1/1
Primary tissues
Normal ovary 3/5
Ovarian tumoursa 5/6
Fibroblasts 1/3b
Normal marrow (Russell et al., 1994) 0/9
Presence ofEVI-l RNA by RT-PCR for tumour-derived cell lines,
primary tumour and tissue specimens. Results from leukaemia and
lymphoma specimens, fibroblasts and normal marrow have been
previously reported (Russell et al., 1994). Normal ovarian tissue was
obtained from patients who underwent surgery for non-metastatic
endometrial cancer. aFive carcinomas and one-primary ovarian
sarcoma. bPositive in fetal fibroblasts.
I). Thus, in contrast to previous studies using Northern
analysis (Morishita et al., 1990b), results using RT-PCR
indicate EVI-I RNA is widely expressed in human solid
tumours and in normal ovary.
To verify the presence of the EVI-1 protein in ovarian
tissues, immunostaining of frozen tissues and fresh cells was
performed. Similar to studies ofmurine tissues (Perkins et al.,
1991b), staining of two normal ovaries showed EVI-I protein
essentially limited to oocyte cytoplasm with only faint
stromal staining (Figure 2a). In contrast, immunostaining
of primary ovarian carcinomas was intense in cytoplasm and
present in nuclei (Figure 2b), while controls (Figure 2c) did
not stain. Cytospin preparations of an EVI-1-positive ovarian
cell line, SKOV-3, showed discrete nuclear staining and
1520
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Figure 2 (a) Oocyte cytoplasm from a normal ovary demonstrating intense staining for EVI-l (original magnification x400). (b)
Metastatic ovarian adenocarcinoma (original magnification x 200). EVI-l staining in the cytoplasm with focal nuclear positivity
(counterstain, nuclear fast red). (c) Metastastic ovarian adenocarcinoma control slide (rabbit immunoglobulin), nuclear fast red
counterstain. (d) SKOV-3 cell line (original magnification x 1000) shows punctate, primarily nuclear, staining for EVI-1 (no
counterstain).
minimal or no cytoplasmic staining (Figure 2d). Staining of
2780 cells showed no EVI-1 protein (not shown). These
results indicate that, in contrast to normal ovary, EVI-l
protein is increased and widely expressed in ovarian cancers
showing both cytoplasmic and nuclear distribution.
To compare levels of EVI-1 RNA in normal ovaries and
cancer cell lines, RNAase protection for EVI-1 RNA was
performed (Russell et al., 1994). EVI-1 RNA was not
detected in 2780 or UACC 1598 cells, but was detected at
equal levels using phosphor-imaging of RNA signals from
normal ovaries and the 376 cell line. EVI-1 RNA was
detected by RNAase protection in 11/13 ovarian cell lines
and in HEL leukaemia cells (see Figure 3 for an example).
EVI-I RNA was also detected by RNAase protection in two
out of three melanoma and two out of two prostate cell lines
(not shown).
Using the phosphor-imaging and normalising to GAPDH
levels, EVI-1 RNA expression by normal ovary was assigned
a value of 1.0. Tumour RNA levels were determined on gels
containing normal ovary or 367 RNA. Using this scale, HEL
leukaemia cells expressed 2-4 times and UCSD/AML1
leukaemia cells seven times the level in normal ovary or
367 cells (not shown). Ovarian cell lines expressed 0 to 40
times the level found in the median of three normal ovaries
(Table I). Expression by the SKOV-3 and UACC 295 cell
lines exceeded linearity of the assay, but was estimated at
11-40 times that of normal ovary and at least four times that
of HEL cells. Cell line UACC 1598 contained EVI-1 RNA
detected by RNA PCR, but undetectable EVI-I RNA by
RNAase protection. PC3 prostate cancer cells contained EVI-
1 RNA at levels apparently identical to SKOV-3 cells (not
shown, two experiments). Using Northern blots, the half-life
of EVI-1 RNA from SKOV-3 and Colo-316 cells in the
1 9 3 A ' i 7 8 9 1 2 3 4 5 6 7 8 9
Figure 3 Ribonuclease (RNAase) protection assay of EVI-1
RNA (left) or GADPH (right) in ovarian cancer lines. HL60, lane
1; HEL, lane 2. Left, SKOV-3 (lane 3) is overexpressed relative to
all other lines. Ovarian cell lines 367, 2780, Colo-316, and 2008,
lanes 4, 5, 6 and 7 respectively. 2780 (lane 5) is negative and Colo-
316 (lane 4) is not visible by light photography but is consistently
positive by phosphor-imaging. Digested and undigested yeast
(lanes 8 and 9) are controls for RNAase assay integrity. EVI-I
expression is measured relative to GAPDH expression.
presence of actinomycin-D was 2.5 h, a value nearly identical
to those previously obtained for EVI-I transcripts in UCSD/
AML1 leukaemia and HEC-IB endometrial carcinoma cells
(Oval et al., 1992). Levels of EVI-I RNA 146-153% of
control after exposure to 10 ,ug ml-' cycloheximide for 2 h
(two studies).
Southern blots did not detect rearrangements or amplifica-
tion of EVI-l in ovarian carcinoma cell lines (Table II). In
contrast, a rearrangement predicted from pulse-field maps
(Oval et al., 1992) was detected in UCSD/AML1 DNA
digested with BamHI/EcoRI. The intensity of EVI-I bands
detected on Southern analysis did not differ between normal
diploid ovarian DNA, normal lymphocyte DNA and the
ovarian tumours, indicating that the EVI-1 gene was not
significantly amplified (Table I). Southern blots of 2780 and
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Table II Cytogenetic evaluation and EVI-1 expression in ovarian cancer cell lines
Modal
chromosome EVI-I EVI-1
Cell line number Karyotype Chromosome 3FISH 3q26 FISH DNA RNA
OVCAR3 63-66 Normal 3x2 Nml 3 x2 qdp(3) 7-12 3q26 1.3 10
qdp(3)(q24-q27) signals/cell;
translocation/
inversion of 3q26
SKOV-3 7174 +del(3)(q24) +der(3) 4-6 translocations 1.2 40
involving 3q26
367 49-56 ND ND ND 1.4 1
2008 58 i(3)(plO) Same No 3q26 ND 6
i(3)(qlO) translocations
+del(3)(p14)
Colo-316 61-63 i(3)(plO) add(3)(?) Three translocations 1.2 8
del(3)(q21) add(3)(ql 1) involving 3q26
12 mars 9-10 markers contain
chrom 3 sequences
2780 46 t(X;3)(q24;p21) Same No 3q26 1.0 0
translocations
UACC 57-66 Normal x 1 Same One 3q26 1.4 0
1598 dmin i(3q) x 1 translocation
der(8)t(3;8) x 1
der(3p)hsr(3p)
UACC 61-67 Normal 3xl Same 4-6 3q26 1.2 11
295 der(3)t(1;3) translocations
(q21;p21) x 1
del(3pl3)add(3)
(q31)x 1
add(3)(p21)add(3)
(q24) x 1
Normal 46 Normal 3 x 2 Two normal Two normal signals 1 I
cells chromosome 3
Karyotypes and modesweredetermined asdescribed previously(Thompson etal., 1994). FISH wasperformedusingawholechromosome 3 paint
or 3q26 band-specific probe. EVI-I DNA was determined from Southern blotsprobed formultiple areas ofthe EVI-I gene. Results represent means
offour experiments normalised to either normal ovary or lymphocyte DNA. EVI-1 RNA levels are expressed relative to normal ovary EVI-1 RNA
content using RNAase protection (See Methods). ND, not done.
UACC 1598 carcinoma DNA probed with a full-length EVI-
1 cDNA also showed no rearrangements or deletions,
indicating that failure of these cells to express EVI-I was
not due to bi-allelic gene deletion.
In leukaemia cells, abnormal EVI-1 transcription is
frequently accompanied by rearrangements involving chro-
mosome 3q26, the site of the EVI-I gene (Warrel et al., 1983;
Morishita et al., 1992; Oval et al., 1992). Karyotypes, whole
chromosome 3 and 3q26 band-specific FISH were performed
in nine ovarian cell lines (Table II). UCSD/AML-1 leukaemia
cells known to contain t(3;3)(q21-26) were used as controls
(Figure 4a). OVCAR-3 cells contained a [der(3)] [quad-
ruplication(3)(q24-27)] in addition to two normal chromo-
some 3s. Whole chromosome 3 and 3q26 FISH confirmed
that [der(3)] material was of chromosome 3 origin (Figure
4c). Other cell lines did not have karyotype abnormalities
involving 3q26, but chromosome 3 and 3q26 FISH showed
der(3) chromosomes in SKOV-3 (Figure 4b) and Colo-316
cells, which were not detected by karyotype (Table II). These
findings suggest chromosome 3q26 rearrangements are
involved in EVI-1 overexpression in these cells.
Discussion
EVI-1 is a member of a large family of zinc finger, DNA-
binding proteins (Schleif, 1988; O'Halloran, 1993). These
genes are extremely common, and constitute up to 1% of
some human chromosomes (O'Halloran, 1993). While some
zinc finger genes are clearly transcription factors (e.g. retinoic
acid receptors; Muscenski et al., 1988) or function as tumour-
suppressors (e.g. WTI; Madden et al., 1991; Gessler et al.,
1990), the functions of many members of this gene family
remain unknown.
Expression of EVI-1 was previously documented only in
HECIb endometrial carcinoma cells from which the human
cDNA was cloned (Morishita et al., 1990b). Using RT-PCR,
EVI-1 RNA was not detected in normal blood or marrow
mononuclear cells, but is expressed by acute myelogenous
leukaemia blasts and cells from the marrow of myelodyspla-
sia patients (Russell et al., 1994; Morishita et al., 1992; Oval
et al., 1992). Enforced EVI-l expression in blood cells
antagonises transcriptional regulation by the erythroid/
megakaryocytic-specific GATA-I protein (Kreider et al.,
1993) and blocks erythropoietin-stimulated growth and in
vitro red blood cell differentiation (Kreider et al., 1993). A
fusion gene containing full-length EVI-l and generated by
t(3;21) in AML also blocks haemopoietic cell line differentia-
tion (Tanaka et al., 1995). Recent studies suggest EVI-I and
EVI-1 fusion genes control c-fos transcription and that
consensus EVI-1 binding sequences can act as transcriptional
regulators (Tanaka et al., 1994; Morishita et al., 1995). These
studies indicate EVI-1 controls or modifies expression of
important genes in human cancers, and can control cell
differentiation.
In contrast to previous studies using Northern analyses
(Morishita et al., 1990b), the present studies using RT-PCR
and RNAase protection indicate EVI-I RNA expression is
common in human solid tumours. The RT-PCR assay was
previously shown to be 300 times more sensitive than
RNAase protection and was able to detect one positive
luekaemia cell diluted in 1000 in normal marrow cells
(Russell et al., 1994). Thus, techniques used in the present
studies are at least 3 logs more sensitive than those used in
previous studies of human solid tumours (Morishita et al.,
1990b).
Immunostaining of primary ovarian tumours and cell lines
indicates a relative redistribution of EVI-1 protein from
cytoplasm of normal oocytes to increased nuclear and diffuse
epithelial cytoplasmic locations in ovarian tumours. Thus,
altered EVI-1 expression is accompanied by potential effects
of protein redistribution and overexpression. RNAaseEVI-1 in ovarian cancer
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Figure 4 Fluorescence in situ hybridisation (FISH) with a
chromosome 3q26 probe generated using microdissection. (a)
UCSD/AML1 leukaemia cells containing known t(3;3)(q21;q26).
The probe detects previously demonstrated translocated 3q26
sequences containing EVI-1 (arrow) (Morishita et al., 1992; Oval
et al., 1992). (b) SKOV-3 ovarian carcinoma cells with high EVI-l
RNA levels demonstrating multiple derivative chromosomes
containing 3q26 sequences. Chromosomes shown by arrows were
demonstrated to be abnormal der(3) by whole chromosome FISH
and Giemsa prebanding. (c) OVCAR3 ovarian carcinoma cells
demonstrating inversion/duplication of 3q26 sequences (arrows).
protection assays indicate high-level EVI-l expression in
ovarian carcinoma and other solid tumour cell lines
compared with normal ovary, suggesting EVI-l plays a role
in ovarian tumour progression or pathogenesis. Southern
analyses (Table II) indicate EVI-1 overexpression was not
accompanied by EVI-l gene amplification.
In leukaemia cells, EVI-l transcription is activated by
long-range translocations involving chromosome 3q26 seg-
ments 3' or 5' of the EVI-1 gene (Russell et al., 1993;
Morishita et al., 1992). It is unclear over what distances
chromosome 3 rearrangements can alter EVI-I transcription,
but one case of leukaemia with EVI-I expression with a 3q26
rearrangement was mapped by pulse-field gels up to 900 kb 5'
and 3' of the gene without detecting a rearrangement (Jagasia
et al., 1994). Although further studies are required to
delineate mechanisms controlling EVI-1 expression in
ovarian carcinoma cells, the half-life of EVI-I RNA was
identical to values in acute leukaemia and endometrial
carcinoma cells (Oval et al., 1992). Despite this finding,
Southern analyses did not show EVI-I amplification or
rearrangements (Table II). These findings suggest EVI-I
expression is also regulated by transcription in ovarian cancer
cells. Although only one ovarian carcinoma cell line with
increased EVI-I RNA showed a definite karyotype abnorm-
ality involving band 3q26, using FISH, lines with relative
EVI-I overexpression showed rearrangements using a 3q26
band-specific probe. These studies suggest that rearrange-
ments involving 3q26 are involved in abnormal EVI-1
expression in non-haemopoietic tumours as well.
The role and regulation of EVI-1 in non-haematological
tissues are unknown. Sequential expression of EVI-I in
ontogeny suggests a role in cell migration or adhesion
(Perkins et al., 1991b). EVI-I is also highly conserved
among species and recent studies in nematodes indicate it is
highly homologous to a zinc finger binding protein, egl-43,
important in long-range migration of (hermaphrodite-
specific) motor neurons (Garriga et al., 1993). Further
studies investigating potential role(s) of EVI-I by gene
transfer in ovarian tumours are in progress.
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